1. Recent Articles

    1. Hypoxia and hypoxia-inducible factors in neuroblastoma.

      Hypoxia and hypoxia-inducible factors in neuroblastoma.

      Cell Tissue Res. 2017 Oct 14;:

      Authors: Påhlman S, Mohlin S

      Abstract Hypoxia (i.e., low oxygen levels) is a known feature of aggressive tumors. Cells, including tumor cells, respond to conditions of insufficient oxygen by activating a transcriptional program mainly driven by hypoxia-inducible factors (HIF)-1 and HIF-2.

      Read Full Article
    2. LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      Oncotarget. 2017 Sep 12;8(39):65620-65626

      Authors: Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, Yang L, Yan L

      Abstract Previous genome-wide association and validation studies suggest that LIM domain only 1 (LMO1) gene polymorphisms affect neuroblastoma susceptibility.

      Read Full Article
    3. A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model.

      A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model.

      Oncotarget. 2017 Sep 12;8(39):64728-64744

      Authors: Aminzadeh-Gohari S, Feichtinger RG, Vidali S, Locker F, Rutherford T, O'Donnel M, Stöger-Kleiber A, Mayr JA, Sperl W, Kofler B

      Read Full Article
      Mentions: Chemotherapy
    4. Zebrafish as a model to study neuroblastoma development.

      Zebrafish as a model to study neuroblastoma development.

      Cell Tissue Res. 2017 Oct 13;:

      Authors: Casey MJ, Stewart RA

      Abstract Neuroblastoma is a pediatric solid tumor arising from embryonic neural crest progenitor cells that normally generate the peripheral sympathetic nervous system.

      Read Full Article
      Mentions: ALK
    5. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study.

      Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study.

      Br J Pharmacol. 2017 Oct 13;:

      Authors: Ryu S, Hayashi M, Aikawa H, Okamoto I, Fujiwara Y, Hamada A

      Read Full Article
      Mentions: ALK Imaging
    6. Nutritional Characteristics of the Diets of Child and Adolescent Cancer Survivors.

      Nutritional Characteristics of the Diets of Child and Adolescent Cancer Survivors.

      J Adolesc Young Adult Oncol. 2017 Oct 12;:

      Authors: Teixeira JFC, Maia-Lemos PDS, Pisani LP

      Abstract PURPOSE: Diseases associated with prior treatment, such as obesity, have been described in cancer survivors. Recent studies have shown that current estimates of overweight do not differ from that in the general population, suggesting the influence of environmental factors, such as dietary intake.

      Read Full Article
      Mentions: Treatment
    7. NIH Funds Pediatric Data Resource Center.

      NIH Funds Pediatric Data Resource Center.

      Cancer Discov. 2017 Oct 11;:

      Authors:

      Abstract Children's Hospital of Philadelphia will lead a collaborative effort-funded with $14.8 million from the NIH-to pool genomic and phenotypic data from tens of thousands of patients to study the causes of pediatric cancer and structural birth defects.

      PMID: 29021134 [PubMed - as supplied by publisher]

      Read Full Article
    8. Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Transl Oncol. 2017 Oct 09;10(6):936-941

      Authors: He J, Zou Y, Wang T, Zhang R, Yang T, Zhu J, Wang F, Xia H

      Abstract Neuroblastoma is one of the most commonly diagnosed solid cancers for children, and genetic factors may play a critical role in neuroblastoma development.

      Read Full Article
    9. Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      J Pediatr Surg. 2017 Sep 11;:

      Authors: Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G

      Abstract BACKGROUND/PURPOSE: The impact of abdominal topography and surgical technique on resectability and local relapse pattern of relapsed abdominal high-risk neuroblastoma (R-HR-NB) is not clearly defined.

      Read Full Article
      Mentions: Treatment Relapse
    10. Invariant natural killer T infiltration in neuroblastoma with favorable outcome.

      Invariant natural killer T infiltration in neuroblastoma with favorable outcome.

      Pediatr Surg Int. 2017 Oct 10;:

      Authors: Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S

      Abstract BACKGROUND: Tumor immunity has been suggested to play a key role in clinical and biological behavior of neuroblastomas.

      Read Full Article
    11. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Pediatr Surg Int. 2017 Oct 10;:

      Authors: Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S

      Read Full Article
    12. CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells.

      CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells.

      Front Mol Neurosci. 2017;10:310

      Authors: Chaudhari N, Talwar P, Lefebvre D'hellencourt C, Ravanan P

      Abstract Neuroblastoma is the most common solid extra cranial tumor in infants. Improving the clinical outcome of children with aggressive tumors undergoing one of the multiple treatment options has been a major concern.

      Read Full Article
      Mentions: Treatment ALK MYCN
    13. Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma.

      Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma.

      Cancer Cell. 2017 Oct 09;32(4):427-443.e8

      Authors: Delloye-Bourgeois C, Bertin L, Thoinet K, Jarrosson L, Kindbeiter K, Buffet T, Tauszig-Delamasure S, Bozon M, Marabelle A, Combaret V, Bergeron C, Derrington E, Castellani V

      Read Full Article
      Mentions: Metastasis
    14. Neuroblastoma Metastases: Leveraging the Avian Neural Crest.

      Neuroblastoma Metastases: Leveraging the Avian Neural Crest.

      Cancer Cell. 2017 Oct 09;32(4):395-397

      Authors: Zheng T, Ménard M, Weiss WA

      Abstract Neuroblastoma, an embryonal cancer of neural crest origin, shows metastases frequently at diagnosis. In this issue of Cancer Cell, Delloye-Bourgeois and colleagues demonstrate that neuroblastoma cell lines and patient-derived xenografts engraft and adopt a metastatic program in chick embryos.

      Read Full Article
    15. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.

      Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.

      Chem Biol Drug Des. 2017 Oct 10;:

      Authors: Zhang M, Jiang Z, Chen S, Wu Z, Chen K, Wu Y

      Abstract Neuroblastoma (NB) is a highly malignant solid tumor in children. The cysteine endopeptidase legumain is expressed in adult solid tumors, but its expression in NB has not been examined.

      Read Full Article
    16. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (8 articles) Treatment
    2. (5 articles) MYCN
    3. (4 articles) Chemotherapy
    4. (3 articles) ALK
    5. (2 articles) Antibody
  3. Recent Quotes

    1. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    2. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    3. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    4. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    5. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    6. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    7. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    8. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    9. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju
    10. The dBET1 and the dFKBP12 compounds are presently in a late stage of lead optimization for therapeutic development in both cancer and non-malignant diseases, Composition-of-matter and method-of-use patent applications have been filed on these and other additional targeted agents, as well as on the chemistry platform.
      By Prem Das